Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 344

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 344
---
 the adjustments according to Kadimastem’s and NLS’s Unaudited Pro Forma Condensed Combined Balance Sheets as presented in this proxy statement/prospectus on page 269.

165 NLS BUSINESS History and Development of the Company NLS was incorporated on June10, 2015, as a Swiss limited company. In 2016, NLS acquired several patents from Assistance Publique — Hopitaux de Paris, or AP -HP, in France, including for NLS’s lead compound mazindol. Since the founding of NLS, NLS has assembled an experienced leadership team with a track record of developing and repurposing products to treat rare neurological disorders. NLS’s Chief Executive Officer, Alexander Zwyer, has held a variety of senior leadership roles of increasing responsibility in the pharmaceutical industry, including global roles in business development, sales and marketing, medical as well as regulatory affairs, and general management. NLS complements its management team with a group of scientific and clinical advisors that includes internationally recognized North American and European experts in CNS disorders, including the areas of its current focus, rare hypersomnolence (specifically, narcolepsy) and complex neurodevelopmental disorders. NLS’s registered office and principal executive offices are located at The Circle6, 8058 Zurich, Switzerland. NLS’s telephone number in Switzerland is +41.44.512.2150 and its website address is https://nlspharma.com. The SEC also maintains an internet website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. NLS’s filings with the SEC are available to the public through the SEC’s website at www.sec.gov. The information contained on, or that can be accessed through, NLS’s website or the SEC website is not part of this proxy statement/prospectus. The website address has been included in this proxy statement/prospectus solely as an inactive textual reference. NLS is an EGC. As such, NLS is eligible to, and intends to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not “emerging growth companies” such as not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes -OxleyAct. NLS could remain an EGC for up to five years, or until the earliest of (a) the last day of the first fiscal year in which NLS’s annual gross revenues exceeds $1